Roche Holding (ROG) Stock Overview
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
ROG Community Fair Values
Create NarrativeSee what 234 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Roche Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 352.50 |
| 52 Week High | CHF 356.80 |
| 52 Week Low | CHF 231.90 |
| Beta | 0.20 |
| 1 Month Change | 7.40% |
| 3 Month Change | 32.97% |
| 1 Year Change | 23.25% |
| 3 Year Change | 23.90% |
| 5 Year Change | 13.00% |
| Change since IPO | 1,250.58% |
Recent News & Updates
Roche Holding AG (VTX:ROG) Annual Results: Here's What Analysts Are Forecasting For This Year
Feb 03
Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond
About Roche Holding AG Roche is one of the world’s largest pharmaceutical companies, with a market capitalization of approximately CHF 300 billion (USD 380bn). The company operates through two primary divisions: •Roche Pharmaceuticals: A global leader in biotechnology and the leading provider of treatments for cancer.Recent updates
Roche Holding AG (VTX:ROG) Annual Results: Here's What Analysts Are Forecasting For This Year
Feb 03Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond
About Roche Holding AG Roche is one of the world’s largest pharmaceutical companies, with a market capitalization of approximately CHF 300 billion (USD 380bn). The company operates through two primary divisions: •Roche Pharmaceuticals: A global leader in biotechnology and the leading provider of treatments for cancer.Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)
Aug 20These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well
Jun 24Roche Holding (VTX:ROG) Will Pay A Larger Dividend Than Last Year At CHF9.70
Mar 17Roche Holding (VTX:ROG) Has A Pretty Healthy Balance Sheet
Mar 16Roche Holding (VTX:ROG) Is Increasing Its Dividend To CHF9.70
Feb 23Roche Holding (VTX:ROG) Is Paying Out A Larger Dividend Than Last Year
Feb 09Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear
Feb 05Roche Holding will see a 4.2576% revenue growth shaking the market
### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der ErgebnisseRoche hat für das Jahr 2024 ein solides Wachstum von 7 % auf
Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025
Successful Pharma pipeline and innovative diagnostics launches are anticipated to drive long-term revenue growth and operating profit.Shareholder Returns
| ROG | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 0.7% | 0.8% | 1.5% |
| 1Y | 23.3% | 24.8% | 6.2% |
Return vs Industry: ROG underperformed the Swiss Pharmaceuticals industry which returned 24.8% over the past year.
Return vs Market: ROG exceeded the Swiss Market which returned 6.2% over the past year.
Price Volatility
| ROG volatility | |
|---|---|
| ROG Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in CH Market | 9.0% |
| 10% least volatile stocks in CH Market | 1.8% |
Stable Share Price: ROG has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: ROG's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1896 | 103,249 | Thomas Schinecker | www.roche.com |
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions.
Roche Holding AG Fundamentals Summary
| ROG fundamental statistics | |
|---|---|
| Market cap | CHF 281.28b |
| Earnings (TTM) | CHF 12.88b |
| Revenue (TTM) | CHF 63.36b |
Is ROG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROG income statement (TTM) | |
|---|---|
| Revenue | CHF 63.36b |
| Cost of Revenue | CHF 16.16b |
| Gross Profit | CHF 47.19b |
| Other Expenses | CHF 34.31b |
| Earnings | CHF 12.88b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 23, 2026
| Earnings per share (EPS) | 16.19 |
| Gross Margin | 74.49% |
| Net Profit Margin | 20.33% |
| Debt/Equity Ratio | 83.5% |
How did ROG perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/03 02:35 |
| End of Day Share Price | 2026/02/03 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Roche Holding AG is covered by 45 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Staszak | Argus Research Company |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Yihan Li | Barclays |